- The FDA has expanded the Emergency Use Authorization (EUA) label for Quanterix Corporation's QTRX Simoa SARS-CoV-2 N Protein Antigen Test.
- The expanded label will include testing with a nasal swab and saliva samples and asymptomatic serial testing with nasal swab samples.
- The expanded label establishes this test as the first antigen test authorized for use with saliva samples.
- The test is validated to detect all Variants of Concern currently designated by the Centers for Disease Control (CDC).
- The test can run on Quanterix' Simoa HD-X Analyzer, a fully automated high-throughput immunoassay instrument.
- Related Link: Why Cassava Sciences Stock Investors Are Pulling Back.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: QTRX stock closed 3.61% lower at $46.21 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in